Literature DB >> 19317837

Elevated thrombopoietin in plasma of burned patients without and with sepsis enhances platelet activation.

E Lupia1, O Bosco, F Mariano, A E Dondi, A Goffi, T Spatola, A Cuccurullo, P Tizzani, G Brondino, M Stella, G Montrucchio.   

Abstract

BACKGROUND: Thrombopoietin (TPO) is a humoral growth factor that does not induce platelet aggregation per se, but enhances platelet activation in response to several agonists. Circulating levels of TPO are increased in patients with sepsis and are mainly related to sepsis severity.
OBJECTIVES: To investigate the potential contribution of elevated TPO levels in platelet activation during burn injury complicated or not by sepsis.
METHODS: We studied 22 burned patients, 10 without and 12 with sepsis, and 10 healthy subjects. We measured plasma levels of TPO, as well as leukocyte-platelet binding and P-selectin expression. The priming activity of plasma from burned patients or healthy subjects on platelet aggregation and leukocyte-platelet binding, and the role of TPO in these effects were also studied in vitro.
RESULTS: Burned patients without and with sepsis showed higher circulating TPO levels and increased monocyte-platelet binding compared with healthy subjects. Moreover, TPO levels, monocyte-platelet binding and P-selectin expression were significantly higher in burned patients with sepsis than in burned patients without sepsis. In vitro, plasma from burned patients without and with sepsis, but not from healthy subjects, primed platelet aggregation, monocyte-platelet binding and platelet P-selectin expression. The effect of plasma from burned patients with sepsis was significantly higher than that of plasma from burned patients without sepsis. An inhibitor of TPO prevented the priming effect of plasma from burned patients.
CONCLUSIONS: Increased TPO levels may enhance platelet activation during burn injury and sepsis, potentially participating in the pathogenesis of multi-organ failure in these diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19317837     DOI: 10.1111/j.1538-7836.2009.03348.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  18 in total

Review 1.  Obesity and Altered Aspirin Pharmacology.

Authors:  Nicholas B Norgard
Journal:  Clin Pharmacokinet       Date:  2018-06       Impact factor: 6.447

2.  Analysis of factor XIa, factor IXa and tissue factor activity in burn patients.

Authors:  Jeffrey W Shupp; Shannon M Prior; Daniel Y Jo; Lauren T Moffatt; Kenneth G Mann; Saulius Butenas
Journal:  Burns       Date:  2017-10-09       Impact factor: 2.744

3.  Whole blood flow cytometry measurements of in vivo platelet activation in critically-Ill patients are influenced by variability in blood sampling techniques.

Authors:  Matthew T Rondina; Colin K Grissom; Shaohua Men; Estelle S Harris; Hansjorg Schwertz; Guy A Zimmerman; Andrew S Weyrich
Journal:  Thromb Res       Date:  2011-12-16       Impact factor: 3.944

4.  Prognostic Values of Platelet Distribution Width and Platelet Distribution Width-to-Platelet Ratio in Severe Burns.

Authors:  Jian-Chang Lin; Guo-Hua Wu; Jian-Jun Zheng; Zhao-Hong Chen; Xiao-Dong Chen
Journal:  Shock       Date:  2022-04-01       Impact factor: 3.454

Review 5.  Prognostic Value of Platelet to Lymphocyte Ratio in Sepsis: A Systematic Review and Meta-analysis.

Authors:  Gancheng Wang; Azam Mivefroshan; Shirin Yaghoobpoor; Shokoufeh Khanzadeh; Goli Siri; Farzad Rahmani; Samira Aleseidi
Journal:  Biomed Res Int       Date:  2022-06-06       Impact factor: 3.246

6.  Is all plasma created equal? A pilot study of the effect of interdonor variability.

Authors:  Amanda M Chipman; Shibani Pati; Daniel Potter; Feng Wu; Maximillian Lin; Rosemary A Kozar
Journal:  J Trauma Acute Care Surg       Date:  2020-01       Impact factor: 3.697

7.  Circulating primers enhance platelet function and induce resistance to antiplatelet therapy.

Authors:  T A Blair; S F Moore; I Hers
Journal:  J Thromb Haemost       Date:  2015-06-25       Impact factor: 5.824

8.  Blockade of Thrombopoietin Reduces Organ Damage in Experimental Endotoxemia and Polymicrobial Sepsis.

Authors:  Alessandra Cuccurullo; Elisabetta Greco; Enrico Lupia; Paolo De Giuli; Ornella Bosco; Erica Martin-Conte; Tiziana Spatola; Emilia Turco; Giuseppe Montrucchio
Journal:  PLoS One       Date:  2016-03-10       Impact factor: 3.240

9.  Thrombopoietin Contributes to Enhanced Platelet Activation in Patients with Type 1 Diabetes Mellitus.

Authors:  Ornella Bosco; Barbara Vizio; Gabriella Gruden; Martina Schiavello; Bartolomeo Lorenzati; Paolo Cavallo-Perin; Isabella Russo; Giuseppe Montrucchio; Enrico Lupia
Journal:  Int J Mol Sci       Date:  2021-06-29       Impact factor: 5.923

Review 10.  Thrombopoietin as biomarker and mediator of cardiovascular damage in critical diseases.

Authors:  Enrico Lupia; Alberto Goffi; Ornella Bosco; Giuseppe Montrucchio
Journal:  Mediators Inflamm       Date:  2012-04-05       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.